These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 17851877)

  • 1. Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumours.
    Van Der Horst-Schrivers AN; Slot MH; Willemse PH; Kema IP; De Vries EG; Wymenga AN
    Acta Oncol; 2008; 47(1):153-5. PubMed ID: 17851877
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
    Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
    J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in kidney cancer: new indication. Premature approval of this indication.
    Prescrire Int; 2009 Feb; 18(99):10. PubMed ID: 19382401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut neuroendocrine tumors.
    Hammond PJ; Bloom SR
    Curr Ther Endocrinol Metab; 1994; 5():570-5. PubMed ID: 7704795
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
    Hansen CP; Knigge U
    Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metastatic pancreatic neuroendocrine tumors and chemotherapy: evidences and perspectives].
    Gómez Raposo C; Gómez Senent S; González Barón M
    Med Clin (Barc); 2007 Mar; 128(9):357; author reply 357-8. PubMed ID: 17376367
    [No Abstract]   [Full Text] [Related]  

  • 7. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
    Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
    Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?
    Völter V; Peschel C
    J Clin Oncol; 2004 Feb; 22(3):573; author reply 574-5. PubMed ID: 14752089
    [No Abstract]   [Full Text] [Related]  

  • 9. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors.
    Eriksson B; Annibale B; Bajetta E; Mitry E; Pavel M; Platania M; Salazar R; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):214-9. PubMed ID: 19713713
    [No Abstract]   [Full Text] [Related]  

  • 10. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.
    Cassier PA; Walter T; Eymard B; Ardisson P; Perol M; Paillet C; Chayvialle JA; Scoazec JY; Hervieu V; Bohas CL
    Cancer; 2009 Aug; 115(15):3392-9. PubMed ID: 19472402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of somatostatin analogs in the management of carcinoid tumors.
    Tomassetti P; Migliori M; Campana D; Brocchi E; Piscitelli L; Tomassetti V; Corinaldesi R
    J Endocrinol Invest; 2003; 26(8 Suppl):79-81. PubMed ID: 15233219
    [No Abstract]   [Full Text] [Related]  

  • 12. Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours.
    Papamichael D; Seymour MT; Penson RT; Wilson P; Gallagher CJ; Besser GM; Slevin ML
    Eur J Cancer; 1998 Dec; 34(13):2133-4. PubMed ID: 10070325
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical oncology considerations in patients with metastatic neuroendocrine carcinomas.
    Kvols L
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):56-60. PubMed ID: 7992083
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
    Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diversity and individualization of cancer treatment].
    Dietrich PY
    Rev Med Suisse; 2011 May; 7(296):1123-4. PubMed ID: 21721200
    [No Abstract]   [Full Text] [Related]  

  • 16. VEGF-targeted therapy: mechanisms of anti-tumour activity.
    Ellis LM; Hicklin DJ
    Nat Rev Cancer; 2008 Aug; 8(8):579-91. PubMed ID: 18596824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
    Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A
    J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors.
    Oxboel J; Binderup T; Knigge U; Kjaer A
    Oncol Rep; 2009 Mar; 21(3):769-75. PubMed ID: 19212638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
    Noda T; Nagano H; Marubashi S; Kobayashi S; Takeda Y; Murakami M; Tomimaru Y; Dono K; Umeshita K; Nakayama M; Shima T; Wakasa K; Monden M; Doki Y; Mori M
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2099-102. PubMed ID: 19106536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.